PFE vs TTD: Which Is the Better Buy?
Side-by-side comparison of Pfizer Inc. and The Trade Desk, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-16.
Pfizer Inc. · Healthcare
$26.91
+30.1% upside to fair value
Med Conviction
Grade B+
VS
The Trade Desk, Inc. · Technology
$22.76
+488.8% upside to fair value
High Conviction
Grade A-
QuantHub Verdict
TTD has more upside to fair value
(+488.8%).
PFE trades at a lower forward P/E
(9.5x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
PFE |
TTD |
| Current Price |
$26.91 |
$22.76 |
| Fair Value Estimate |
$35.00 |
$134.00 |
| Upside to Fair Value |
+30.1%
|
+488.8%
|
| Market Cap |
$153.0B |
$10.8B |
| Forward P/E |
9.5x
|
24.6x
|
| EV / EBITDA |
13.8x
|
—
|
| Price / Sales |
2.4x
|
3.7x
|
| Price / FCF |
16.8x
|
13.8x
|
| Revenue Growth YoY |
-1.6%
|
+14.5%
|
| Gross Margin |
70.3%
|
78.6%
|
| Operating Margin |
24.7%
|
20.3%
|
| Return on Equity |
9.0%
|
16.9%
|
| Dividend Yield |
6.4% |
— |
| FCF Yield |
5.9%
|
7.3%
|
| Analyst Consensus |
Hold
|
Buy
|
Investment Thesis
Pfizer remains the world's largest traditional pharmaceutical company by non-COVID revenue, generating $62.6B in 2025 sales across oncology, cardiovascular, immunology, and vaccines. The stock trades at a P/S of 2.44x, still well below the 5-year median of 3.10x, driven by post-COVID revenue normalization, a $17-18B patent cliff spanning 2026-2028, and $61.6B in acquisition-related debt from Seag…
The Trade Desk is the largest independent demand-side platform for programmatic advertising with 78.6% gross margins. After recent sell-off, stock trades at 3.2x forward P/S vs historical higher multiples, offering upside if growth stabilizes at 15%+. A-tier business at cheap valuation.[1]
Accumulation Zones
| Metric |
PFE |
TTD |
| Zone Low |
$25.00 |
$100.00 |
| Zone High |
$29.00 |
$114.00 |
| In Buy Zone? |
Yes
|
Yes
|